A hot and cold tumor‑related prognostic signature for stage II colorectal cancer
- Authors:
- Published online on: July 3, 2024 https://doi.org/10.3892/ol.2024.14552
- Article Number: 419
-
Copyright: © Zhou et al. This is an open access article distributed under the terms of Creative Commons Attribution License.
Metrics: Total
Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )
Abstract
Globally, colorectal cancer (CRC) is one of the most lethal and prevalent malignancies. Based on the presence of immune cell infiltration in the tumor microenvironment, CRC can be divided into immunologically ‘hot’ or ‘cold’ tumors, which in turn leads to the differential efficacy of immunotherapy. However, the immune characteristics of hot and cold CRC tumors remain largely elusive, prompting further investigation of their properties regarding the tumor microenvironment. In the present study, a predictive model was developed based on the differential expression of proteins between cold and hot CRC tumors. First, the differentially expressed proteins (DEPs) were identified using digital spatial profiling and mass spectrometry‑based proteomics analysis, and the pathway features of the DEPs were analyzed using functional enrichment analysis. A novel eight‑gene signature prognostic risk model was developed (IDO1, MAT1A, NPEPL1, NT5C, PTGR2, RPL29, TMEM126A and TUBB4B), which was validated using data obtained from The Cancer Genome Atlas. The results revealed that the risk score of the eight‑gene signature acted as an independent prognostic indicator in patients with stage II CRC (T3‑4N0M0). It was also found that a high‑risk score in the eight‑gene signature was associated with high immune cell infiltration in patients with CRC. Taken together, these findings revealed some of the differential immune characteristics of hot and cold CRC tumors, and an eight‑gene signature prognostic risk model was developed, which may serve as an independent prognostic indicator for patients with stage II CRC (T3‑4N0M0).
